A previous study on metastatic ER + /HER2- breast cancer showed moderately lower frequencies (35%) of patients having a PIK3CA mutation when assessing with NGS techniques, and out of these 20% had non-hotspot mutations22. This evidence concerns the gene ERBB2 and breast cancer.